Atossa Genetics Inc. (NASDAQ:ATOS) Stock Has Consensus Price Target of $20.33

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been given an average rating of “Hold” by the five research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $20.33.

A number of brokerages have recently issued reports on ATOS. Wall Street Zen upgraded shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Rodman & Renshaw began coverage on shares of Atossa Genetics in a research note on Tuesday, July 7th. They set a “buy” rating and a $12.00 target price for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Atossa Genetics in a report on Tuesday, September 8th.

Atossa Genetics Trading Down 6.0%

Shares of ATOS stock opened at $2.05 on Friday. Atossa Genetics has a 1-year low of $1.70 and a 1-year high of $19.35. The stock has a market cap of $20.46 million, a price-to-earnings ratio of -0.66 and a beta of 1.27. The stock has a 50-day moving average of $2.43 and a 200-day moving average of $3.66.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.07. Sell-side analysts forecast that Atossa Genetics will post -3.95 earnings per share for the current year.

Institutional Trading of Atossa Genetics

A hedge fund recently bought a new stake in Atossa Genetics stock. State Street Corp bought a new stake in shares of Atossa Genetics Inc. (NASDAQ:ATOS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 39,761 shares of the company’s stock, valued at approximately $77,000. State Street Corp owned 0.40% of Atossa Genetics as of its most recent SEC filing. Institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc, now operating as Atossa Therapeutics, Inc (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other diseases affecting breast tissue. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s principal investigational product is oral endoxifen, a selective estrogen receptor modulator being evaluated in clinical studies involving patients with hormone receptor-positive breast cancer.